Nyxoah SA (NASDAQ:NYXH – Get Free Report) was the recipient of a significant decrease in short interest during the month of February. As of February 13th, there was short interest totaling 237,379 shares, a decrease of 17.8% from the January 29th total of 288,814 shares. Based on an average daily trading volume, of 32,908 shares, the days-to-cover ratio is presently 7.2 days. Currently, 0.7% of the company’s stock are short sold. Currently, 0.7% of the company’s stock are short sold. Based on an average daily trading volume, of 32,908 shares, the days-to-cover ratio is presently 7.2 days.
Analyst Ratings Changes
Several brokerages recently commented on NYXH. Piper Sandler reiterated an “overweight” rating and set a $9.00 price target (down from $12.00) on shares of Nyxoah in a research note on Friday, November 14th. Stifel Nicolaus reduced their price objective on shares of Nyxoah from $12.00 to $11.00 and set a “buy” rating for the company in a research report on Thursday, January 29th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Nyxoah in a report on Monday, December 29th. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $11.67.
Get Our Latest Research Report on NYXH
Institutional Trading of Nyxoah
Nyxoah Stock Performance
Shares of NASDAQ:NYXH traded down $0.27 during midday trading on Tuesday, hitting $3.75. 57,297 shares of the stock were exchanged, compared to its average volume of 51,489. Nyxoah has a twelve month low of $3.74 and a twelve month high of $11.87. The company has a current ratio of 1.70, a quick ratio of 1.41 and a debt-to-equity ratio of 0.40. The company has a 50 day moving average price of $4.70 and a 200-day moving average price of $5.11.
Nyxoah Company Profile
Nyxoah SA, headquartered in Mont-Saint-Guibert, Belgium, is a medical technology company focused on neuromodulation therapies for sleep‐disordered breathing. Established in 2018, the company’s primary offering is the Genio® system, a minimally invasive bilateral hypoglossal nerve stimulator designed to treat moderate to severe obstructive sleep apnea (OSA). By electrically stimulating the genioglossus muscle, the device helps maintain airway patency during sleep, reducing apnea events and improving overall sleep quality.
The Genio system comprises a small, implantable stimulator positioned submentally and an external activation unit worn by the patient.
Featured Stories
- Five stocks we like better than Nyxoah
- The gold chart Wall Street is terrified of…
- America’s 1776 happening again
- Buy this Gold Stock Before May 2026
- What a Former CIA Agent Knows About the Coming Collapse
- “Fed Proof” Your Bank Account with THESE 4 Simple Steps
Receive News & Ratings for Nyxoah Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nyxoah and related companies with MarketBeat.com's FREE daily email newsletter.
